Antiviral Drugs Market

Antiviral Drugs Market (Disease Indication - Hepatitis Virus Infection, HIV Infection, and Respiratory Virus Infection; Product Type - Branded Drugs and Generic Drugs; Distribution Channels - Hospital Pharmacy Store, Retail Pharmacy Store, and Online Pharmacy) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2016 - 2024

  • Rep Id : TMRGL21083
  • Published On : Mar 2017
  • No. of Pages : 184
  • Category : Pharmaceutical

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights
2. Assumptions and Research Methodology

3. Executive Summary: Global Antiviral Drugs Market

4. Market Overview
     4.1. Introduction
            4.1.1. Disease Indication Definition
            4.1.2. Industry Evolution / Developments
     4.2. Overview
     4.3. Key Market Indicators
     4.4. Market Dynamics
            4.4.1. Drivers
            4.4.2. Restraints
            4.4.3. Opportunity
     4.5. Global Antiviral Drugs Market Analysis and Forecasts, 2014–2024
            4.5.1. Market Revenue Projections (US$ Mn)
     4.6. Porter’s Five Force Analysis
     4.7. Market Outlook
     4.8. Antiviral Drugs: FDA Approvals and Patent Expiries by each drug class 
     4.9. Global relative prevalence rate of each hepatitis genotype infection
     4.10. Global relative prevalence rate of HIV infection
     4.11. Pipeline Analysis: Major Market Players

5. Global Antiviral Drugs Market Analysis and Forecasts, By Disease Indication 
     5.1. Introduction & Definition
     5.2. Key Findings / Developments
     5.3. Key Trends
     5.4. Market Value Forecast by Disease Indication, 2014–2024
            5.4.1. Hepatitis Virus Infection
            5.4.2. HIV Infection
            5.4.3. Respiratory Virus Infection
            5.4.4. Others
     5.5. Market Attractiveness by Disease Indication 

6. Global Antiviral Drugs Market Analysis and Forecasts, by Product Type 
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Key Trends
     6.4. Market Value Forecast by Product Type, 2014–2024
            6.4.1. Branded Drugs
            6.4.2. Generic Drugs
     6.5. Market Attractiveness by Product Type 

7. Global Antiviral Drugs Market Analysis and Forecasts, by Distribution Channels 
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Key Trends
     7.4. Market Value Forecast by Distribution Channels, 2014–2024
            7.4.1. Hospital Pharmacy Store
            7.4.2. Retail Pharmacy Store
            7.4.3. Online Pharmacy
     7.5. Market Attractiveness by Distribution Channels 

8. Global Antiviral Drugs Market Analysis and Forecasts, by Region
     8.1. Key Findings
     8.2. Policies and Regulations
     8.3. Market Value Forecast by Region
            8.3.1. North America 
            8.3.2. Europe 
            8.3.3. Asia Pacific 
            8.3.4. Latin America 
            8.3.5. Middle East and Africa 
     8.4. Market Attractiveness by Country/Region

9. North America Antiviral Drugs Market Analysis and Forecast
     9.1. Introduction
            9.1.1. Key Findings
            9.1.2. Policies and Regulations
            9.1.3. Key Trends
     9.2. Market Value Forecast by Disease Indication, 2014–2024
            9.2.1. Hepatitis Virus Infection
            9.2.2. HIV Infection
            9.2.3. Respiratory Virus Infection
            9.2.4. Others
     9.3. Market Value Forecast by Product Type, 2014–2024
            9.3.1. Branded Drugs
            9.3.2. Generic Drugs
     9.4. Market Value Forecast by Distribution Channels, 2014–2024
            9.4.1. Hospital Pharmacy Store
            9.4.2. Retail Pharmacy Store
            9.4.3. Online Pharmacy
     9.5. Market Value Forecast by Country, 2014–2024
            9.5.1. U.S.
            9.5.2. Canada
     9.6. Market Attractiveness Analysis 
            9.6.1. By Disease Indication 
            9.6.2. By Product Type 
            9.6.3. By Distribution Channels 
            9.6.4. By Country

10. Europe Antiviral Drugs Market Analysis and Forecast
     10.1. Introduction
            10.1.1. Key Findings
            10.1.2. Policies and Regulations
            10.1.3. Key Trends
     10.2. Market Value Forecast by Disease Indication, 2014–2024
            10.2.1. Hepatitis Virus Infection
            10.2.2. HIV Infection
            10.2.3. Respiratory Virus Infection
            10.2.4. Others
     10.3. Market Value Forecast by Product Type, 2014–2024
            10.3.1. Branded Drugs
            10.3.2. Generic Drugs
     10.4. Market Value Forecast by Distribution Channels, 2014–2024
            10.4.1. Hospital Pharmacy Store
            10.4.2. Retail Pharmacy Store
            10.4.3. Online Pharmacy
     10.5. Market Value Forecast by Country, 2014–2024
            10.5.1. U.K.
            10.5.2. Germany
            10.5.3. France
            10.5.4. Italy
            10.5.5. Spain
            10.5.6. Russia
            10.5.7. Rest of Europe
     10.6. Market Attractiveness Analysis 
            10.6.1. By Disease Indication 
            10.6.2. By Product Type 
            10.6.3. By Distribution Channels 
            10.6.4. By Country

11. Asia Pacific Antiviral Drugs Market Analysis and Forecast
     11.1. Introduction
            11.1.1. Key Findings
            11.1.2. Policies and Regulations
            11.1.3. Key Trends
     11.2. Market Value Forecast by Disease Indication, 2014–2024
            11.2.1. Hepatitis Virus Infection
            11.2.2. HIV Infection
            11.2.3. Respiratory Virus Infection
            11.2.4. Others
     11.3. Market Value Forecast by Product Type, 2014–2024
            11.3.1. Branded Drugs
            11.3.2. Generic Drugs
     11.4. Market Value Forecast by Distribution Channels, 2014–2024
            11.4.1. Hospital Pharmacy Store
            11.4.2. Retail Pharmacy Store
            11.4.3. Online Pharmacy
     11.5. Market Value Forecast by Country, 2014–2024
            11.5.1. India
            11.5.2. China
            11.5.3. Japan
            11.5.4. Australia & New Zealand
            11.5.5. Rest of Asia Pacific
     11.6. Market Attractiveness Analysis 
            11.6.1. By Disease Indication 
            11.6.2. By Product Type 
            11.6.3. By Distribution Channels 
            11.6.4. By Country

12. Latin America Antiviral Drugs Market Analysis and Forecast
     12.1. Introduction
            12.1.1. Key Findings
            12.1.2. Policies and Regulations
            12.1.3. Key Trends
     12.2. Market Value Forecast by Disease Indication, 2014–2024
            12.2.1. Hepatitis Virus Infection
            12.2.2. HIV Infection
            12.2.3. Respiratory Virus Infection
            12.2.4. Others
     12.3. Market Value Forecast by Product Type, 2014–2024
            12.3.1. Branded Drugs
            12.3.2. Generic Drugs
     12.4. Market Value Forecast by Distribution Channels, 2014–2024
            12.4.1. Hospital Pharmacy Store
            12.4.2. Retail Pharmacy Store
            12.4.3. Online Pharmacy
     12.5. Market Value Forecast by Country, 2014–2024
            12.5.1. Brazil
            12.5.2. Mexico
            12.5.3. Rest of Latin America
     12.6. Market Attractiveness Analysis 
            12.6.1. By Disease Indication 
            12.6.2. By Product Type 
            12.6.3. By Distribution Channels 
            12.6.4. By Country

13. Middle East and Africa Antiviral Drugs Market Analysis and Forecast
     13.1. Introduction
            13.1.1. Key Findings
            13.1.2. Policies and Regulations
            13.1.3. Key Trends
     13.2. Market Value Forecast by Disease Indication, 2014–2024
            13.2.1. Hepatitis Virus Infection
            13.2.2. HIV Infection
            13.2.3. Respiratory Virus Infection
            13.2.4. Others
     13.3. Market Value Forecast by Product Type, 2014–2024
            13.3.1. Branded Drugs
            13.3.2. Generic Drugs
     13.4. Market Value Forecast by Distribution Channels, 2014–2024
            13.4.1. Hospital Pharmacy Store
            13.4.2. Retail Pharmacy Store
            13.4.3. Online Pharmacy
     13.5. Market Value Forecast by Country, 2014–2024
            13.5.1. South Africa
            13.5.2. GCC Countries
            13.5.3. Rest of Middle East and Africa
     13.6. Market Attractiveness Analysis 
            13.6.1. By Disease Indication 
            13.6.2. By Product Type 
            13.6.3. By Distribution Channels 
            13.6.4. By Country

14. Competition Landscape
     14.1. Market Player – Competition Matrix (By Tier and Size of companies)
     14.2. Market Share Analysis by Company – 2016 (Estimated)
     14.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
            14.3.1. AbbVie, Inc. 
                      14.3.1.1 Company Overview (HQ, Business Segments, Employee Strengths)
                      14.3.1.2 Financial Overview
                      14.3.1.3 Product Portfolio
                      14.3.1.4 SWOT Analysis
                      14.3.1.5 Strategic Overview
            14.3.2. Bristol-Myers Squibb Company 
                      14.3.2.1 Company Overview (HQ, Business Segments, Employee Strengths)
                      14.3.2.2 Financial Overview
                      14.3.2.3 Product Portfolio
                      14.3.2.4 SWOT Analysis
                      14.3.2.5 Strategic Overview
            14.3.3. Cipla, Inc. 
                      14.3.3.1 Company Overview (HQ, Business Segments, Employee Strengths)
                      14.3.3.2 Financial Overview
                      14.3.3.3 Product Portfolio
                      14.3.3.4 SWOT Analysis
                      14.3.3.5 Strategic Overview
            14.3.4. F. Hoffmann-La Roche Ltd. 
                      14.3.4.1 Company Overview (HQ, Business Segments, Employee Strengths)
                      14.3.4.2 Financial Overview
                      14.3.4.3 Product Portfolio
                      14.3.4.4 SWOT Analysis
                      14.3.4.5 Strategic Overview
            14.3.5. Gilead Sciences, Inc. 
                      14.3.5.1 Company Overview (HQ, Business Segments, Employee Strengths)
                      14.3.5.2 Financial Overview
                      14.3.5.3 Product Portfolio
                      14.3.5.4 SWOT Analysis
                      14.3.5.5 Strategic Overview
            14.3.6. GlaxoSmithKline plc.
                      14.3.6.1 Company Overview (HQ, Business Segments, Employee Strengths)
                      14.3.6.2 Financial Overview
                      14.3.6.3 Product Portfolio
                      14.3.6.4 SWOT Analysis
                      14.3.6.5 Strategic Overview
            14.3.7. Johnson & Johnson 
                      14.3.7.1 Company Overview (HQ, Business Segments, Employee Strengths)
                      14.3.7.2 Financial Overview
                      14.3.7.3 Product Portfolio
                      14.3.7.4 SWOT Analysis
                      14.3.7.5 Strategic Overview
            14.3.8. Merck & Co., Inc. 
                      14.3.8.1 Company Overview (HQ, Business Segments, Employee Strengths)
                      14.3.8.2 Financial Overview
                      14.3.8.3 Product Portfolio
                      14.3.8.4 SWOT Analysis
                      14.3.8.5 Strategic Overview
            14.3.9. Mylan N.V. 
                      14.3.9.1 Company Overview (HQ, Business Segments, Employee Strengths)
                      14.3.9.2 Financial Overview
                      14.3.9.3 Product Portfolio
                      14.3.9.4 SWOT Analysis
                      14.3.9.5 Strategic Overview
            14.3.10. Teva Pharmaceutical Industries Ltd. 
                      14.3.10.1 Company Overview (HQ, Business Segments, Employee Strengths)
                      14.3.10.2 Financial Overview
                      14.3.10.3 Product Portfolio
                      14.3.10.4 SWOT Analysis
                      14.3.10.5 Strategic Overview
            14.3.11. Others

List of Tables

Table 01: Global Antiviral Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2014–2024
Table 02: Global Antiviral Drugs Market Size (US$ Mn) Forecast, by Product, 2014–2024
Table 03: Global Antiviral Drugs Market Size (US$ Mn) Forecast, by Distribution Channels, 2014–2024
Table 04: Global Antiviral Drugs Market Size (US$ Mn) Forecast, by Region, 2014–2024
Table 05: North America Antiviral Drugs Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 06: North America Antiviral Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2014–2024
Table 07: North America Antiviral Drugs Market Size (US$ Mn) Forecast, by Product, 2014–2024
Table 08: North America Antiviral Drugs Market Size (US$ Mn) Forecast, by Distribution Channels, 2014–2024
Table 09: Europe Antiviral Drugs Market Size (US$ Mn) Forecast, by Country/Region, 2014–2024
Table 10: Europe Antiviral Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2014–2024
Table 11: Europe Antiviral Drugs Market Size (US$ Mn) Forecast, by Product, 2014–2024
Table 12: Europe Antiviral Drugs Market Size (US$ Mn) Forecast, by Distribution Channels, 2014–2024
Table 13: Asia Pacific Antiviral Drugs Market Size (US$ Mn) Forecast, by Country/ Region, 2014–2024
Table 14: Asia Pacific Antiviral Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2014–2024
Table 15: Asia Pacific Antiviral Drugs Market Size (US$ Mn) Forecast, by Product, 2014–2024
Table 16: Asia Pacific Antiviral Drugs Market Size (US$ Mn) Forecast, by Distribution Channels, 2014–2024
Table 17: Latin America Antiviral Drugs Market Size (US$ Mn) Forecast, by Country/Region, 2014–2024
Table 18: Latin America Antiviral Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2014–2024
Table 19: Latin America Antiviral Drugs Market Size (US$ Mn) Forecast, by Product, 2014–2024
Table 20: Latin America Antiviral Drugs Market Size (US$ Mn) Forecast, by Distribution Channels, 2014–2024
Table 21: MEA Antiviral Drugs Market Size (US$ Mn) Forecast, by Country/ Region, 2014–2024
Table 22: Middle East & Africa Antiviral Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2014–2024
Table 23: Middle East & Africa Antiviral Drugs Market Size (US$ Mn) Forecast, by Product, 2014–2024
Table 24: Middle East & Africa Antiviral Drugs Market Size (US$ Mn) Forecast, by Distribution Channels, 2014–2024

List of Figures

Figure 01: Global Antiviral Drugs Market Size (US$ Mn) Forecast, 2014–2024
Figure 02: FDA Approvals
Figure 03: FDA Approvals
Figure 04: FDA Approvals
Figure 05: FDA Approvals
Figure 06: FDA Approvals
Figure 07: FDA Approvals
Figure 08: FDA Approvals
Figure 09: FDA Approvals
Figure 10: HIV Prevalence
Figure 11: Hepatitis c virus prevalence
Figure 12: Pipeline Analysis
Figure 13: Global Antiviral Drugs Market Value Share Analysis, Disease Indication, 2016 and 2024
Figure 14: Global Hepatitis Virus Infection Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 15: Global HIV Infection Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 16: Global Respiratory Virus Infection Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 17: Global Other Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 18: Antiviral Drugs Market Attractiveness Analysis, Disease Indication, 2016–2024
Figure 19: Global Antiviral Drugs Market Value Share Analysis, by Product, 2016 and 2024
Figure 20: Global Branded Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 21: Global Generic Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 22: Antiviral Drugs Market Attractiveness Analysis, by Product, 2016–2024 
Figure 23: Global Antiviral Drugs Market Value Share Analysis, by distribution Channels, 2016 and 2024
Figure 24: Global Hospital Pharmacy Store Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 25: Global Retail Pharmacy Store Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 26: Global Online Pharmacy Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 27: Antiviral Drugs Market Attractiveness Analysis, by Distribution Channels, 2016–2024
Figure 28: Global Antiviral Drugs Market Value Share Analysis, by Region, 2016 and 2024
Figure 29: Antiviral Drugs Market Attractiveness Analysis, by Region, 2016–2024
Figure 30: North America Antiviral Drugs Market Size (US$ Mn) Forecast, 2014–2024
Figure 31: North America Market Attractiveness Analysis, by Country, 2016–2024
Figure 32: North America Market Value Share Analysis, by Country, 2016 and 2024
Figure 33: North America Antiviral Drugs Market Value Share Analysis, Disease Indication, 2016 and 2024
Figure 34: North America Antiviral Drugs Market Value Share Analysis, by Product, 2016 and 2024
Figure 35: North America Antiviral Drugs Market Value Share Analysis, by distribution Channels, 2016 and 2024
Figure 36: North America Market Attractiveness Analysis, by Disease Indication, 2016-2024
Figure 37: North America Market Attractiveness Analysis, by Product, 2016-2024
Figure 38: North America Market Attractiveness Analysis, by Distribution Channels, 2016-2024
Figure 39: Europe Antiviral Drugs Market Size (US$ Mn) Forecast, 2014–2024
Figure 40: Europe Market Attractiveness Analysis, by Country/ Region, 2016–2024
Figure 41: Europe Market Value Share Analysis, by Country/Region, 2016 and 2024
Figure 42: Europe Antiviral Drugs Market Value Share Analysis, Disease Indication, 2016 and 2024
Figure 43: Europe Antiviral Drugs Market Value Share Analysis, by Product, 2016 and 2024
Figure 44: Europe Antiviral Drugs Market Value Share Analysis, by distribution Channels, 2016 and 2024
Figure 45: Europe Market Attractiveness Analysis, by Disease Indication, 2016-2024
Figure 46: Europe Market Attractiveness Analysis, by Product, 2016-2024
Figure 47: Europe Market Attractiveness Analysis, by Distribution Channels, 2016-2024
Figure 48: Asia Pacific Antiviral Drugs Market Size (US$ Mn) Forecast, 2014–2024
Figure 49: Asia Pacific Market Attractiveness Analysis, by Country/Region, 2016–2024
Figure 50: Asia Pacific Market Value Share Analysis, by Country/ Region, 2016 and 2024
Figure 51: Asia Pacific Antiviral Drugs Market Value Share Analysis, Disease Indication, 2016 and 2024
Figure 52: Asia Pacific Antiviral Drugs Market Value Share Analysis, by Product, 2016 and 2024
Figure 53: Asia Pacific Antiviral Drugs Market Value Share Analysis, by distribution Channels, 2016 and 2024
Figure 54: Asia Pacific Market Attractiveness Analysis, by Disease Indication, 2016-2024
Figure 55: Asia Pacific Market Attractiveness Analysis, by Product, 2016-2024
Figure 56: Asia Pacific Market Attractiveness Analysis, by Distribution Channels, 2016-2024
Figure 57: Latin America Antiviral Drugs Market Size (US$ Mn) Forecast, 2014–2024
Figure 58: Latin America Market Attractiveness Analysis, by Country/Region, 2016–2024
Figure 59: Latin America Antiviral Drugs Market Value Share Analysis, by Country/Region, 2016 and 2024
Figure 60: Latin America Antiviral Drugs Market Value Share Analysis, Disease Indication, 2016 and 2024
Figure 61: Latin America Antiviral Drugs Market Value Share Analysis, by Product, 2016 and 2024
Figure 62: Latin America Antiviral Drugs Market Value Share Analysis, by distribution Channels, 2016 and 2024
Figure 63: Latin America Market Attractiveness Analysis, by Disease Indication, 2016-2024
Figure 64: Latin America Market Attractiveness Analysis, by Product, 2016-2024
Figure 65: Latin America Market Attractiveness Analysis, by Distribution Channels, 2016-2024
Figure 66: MEA Antiviral Drugs Market Size (US$ Mn) Forecast, 2014–2024
Figure 67: MEA Market Attractiveness Analysis, by Country/ Region, 2016-2024
Figure 68: MEA Antiviral Drugs Market Value Share Analysis, by Country/Region, 2016 and 2024
Figure 69: Middle East & Africa Antiviral Drugs Market Value Share Analysis, Disease Indication, 2016 and 2024
Figure 70: Middle East & Africa Antiviral Drugs Market Value Share Analysis, by Product, 2016 and 2024
Figure 71: Middle East & Africa Antiviral Drugs Market Value Share Analysis, by distribution Channels, 2016 and 2024
Figure 72: Middle East & Africa Market Attractiveness Analysis, by Disease Indication, 2016-2024
Figure 73: Middle East & Africa Market Attractiveness Analysis, by Product, 2016-2024
Figure 74: Middle East & Africa Market Attractiveness Analysis, by Distribution Channels, 2016-2024
Figure 75: Global Antiviral Drugs Market Share Analysis, by Company, (2015)

.